Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$44.15
$44.17
$16.02
$45.23
$913.91M1.03704,539 shs1.24 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.21
+0.8%
$10.13
$8.67
$17.82
$589.31M1745,511 shs796,103 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.74
-0.5%
$4.31
$3.63
$7.63
$1.14B1.022.41 million shs3.32 million shs
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
$11.83
$11.83
$3.21
$18.22
$621.21M1.781.52 million shs1,084 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.02
-25.8%
$0.03
$0.02
$6.93
$596K1.318.06 million shs68,328 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
+0.77%-1.81%-1.71%-23.19%-15.12%
MannKind Corporation stock logo
MNKD
MannKind
-0.53%-1.58%-10.10%-24.44%-28.35%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
0.00%0.00%0.00%0.00%0.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-25.75%-17.78%-17.47%-13.95%-99.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
4.0444 of 5 stars
3.50.00.03.53.33.30.6
MannKind Corporation stock logo
MNKD
MannKind
3.0552 of 5 stars
3.61.00.00.02.61.71.9
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
4.3106 of 5 stars
3.15.00.04.31.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00
N/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75157.87% Upside
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.33176.29% Upside
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3314,915.02% Upside

Current Analyst Ratings Breakdown

Latest SYRS, EOLS, ALBO, MNKD, and STML Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/10/2025
MannKind Corporation stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
4/9/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/9/2025
MannKind Corporation stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$40.58M22.52N/AN/A$9.11 per share4.85
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.23N/AN/A$0.09 per share102.33
MannKind Corporation stock logo
MNKD
MannKind
$285.50M3.98$0.14 per share27.09($0.29) per share-12.90
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
$43.22M14.37N/AN/A$3.26 per share3.63
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K1.54N/AN/A$0.79 per share0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1037.4016.26N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
-$76.82M-$1.83N/AN/AN/A-150.30%-48.14%-41.35%N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2025 (Estimated)

Latest SYRS, EOLS, ALBO, MNKD, and STML Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/A
6.32
6.23
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/A
7.43
7.37
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
94.25%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
75.80%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
6.90%
Evolus, Inc. stock logo
EOLS
Evolus
6.10%
MannKind Corporation stock logo
MNKD
MannKind
3.00%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
11.20%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
13020.70 million19.27 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.54 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million294.82 millionOptionable
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
9252.51 millionN/AOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable

Recent News About These Companies

Syros Pharmaceuticals trading resumes
Syros Pharmaceuticals Plans to Wind Down Operations
SYRS’s Latest Surge: What’s Behind the Spike?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Albireo Pharma stock logo

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.21 +0.07 (+0.77%)
Closing price 06/30/2025 04:00 PM Eastern
Extended Trading
$9.20 -0.01 (-0.05%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.74 -0.02 (-0.53%)
Closing price 06/30/2025 04:00 PM Eastern
Extended Trading
$3.74 0.00 (0.00%)
As of 08:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Stemline Therapeutics stock logo

Stemline Therapeutics NASDAQ:STML

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.02 -0.01 (-25.75%)
As of 06/30/2025 03:59 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.